Kanglin Biotec

Kanglin Biotech is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative gene therapies. The company focuses on utilizing Adeno-Associated Virus (AAV) vector technology to treat rare genetic disorders and chronic diseases. Its lead program, KL003, is an AAV-based gene therapy for Hemophilia B currently undergoing clinical evaluation in Phase 1/2 trials. Beyond hematology, Kanglin is expanding its pipeline into neurodegenerative diseases like Parkinson's and other metabolic conditions. The company leverages its proprietary AAV design and high-titer manufacturing platforms to ensure scalability and efficacy. Kanglin aims to provide one-time curative treatments for patients with limited therapeutic options.